GLOW 70 GHK-CU (50mg) / BPC-157 (10mg) / TB500 (10mg)
The Science
Overview
BPC-157 and TB500 contribute companion cytoprotective and angiogenic activity, supporting integrated study of repair across signaling pathways.
Laboratory Observations
Research-Observed Areas of Interest
High Copper-Peptide Load
Suited to research models requiring sustained or intensive GHK-Cu activity, including longer-duration matrix-remodeling studies.
Multi-Pathway Repair
Combines matrix synthesis, cytoprotective, and angiogenic peptides in one standardized research vial.
Reproducible Ratios
Pre-blended formulation standardizes peptide ratios across research replicates.
Bridge Between GLOW 50 and KLOW
Sits between GLOW 50 (lower GHK-Cu) and KLOW (adds KPV anti-inflammatory) in the product line.
Mechanism of Action
Mechanism of Action
Intensive Matrix Remodeling
Higher GHK-Cu loading drives more sustained engagement of copper-dependent matrix enzymes including lysyl oxidase, lysyl hydroxylase, and downstream collagen cross-linking activity.
Cytoprotective Co-Signaling
BPC-157 modulates VEGF and growth-factor expression implicated in connective-tissue and gut-barrier research.
Angiogenic Support
TB500 promotes endothelial migration and microvascular sprouting in wound-healing research models.
Research-Only Notice
GLOW 70 GHK-CU (50mg) / BPC-157 (10mg) / TB500 (10mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.